Fibrinogen-Like Protein 1 (FGL1): Immune Modulation, Cancer Therapy Potential, and Metabolic Regulation
Endocrinology Diagnostics
Basic Properties and Role
- Liver-secreted glycoprotein from fibrinogen family
- Structurally similar to fibrinogen but lacks clotting function
- Primarily involved in liver recovery and metabolism
- Recently identified as important in cancer immunity
Metabolic and Liver Functions
- Supports liver healing and regeneration
- Production increases during liver injury
- Involved in managing fats and insulin resistance
- Linked to obesity and metabolic syndrome
Immune System Interaction
- Binds to LAG-3 (Lymphocyte Activation Gene-3) receptor
- Acts as immune checkpoint by limiting T-cell activity
- Helps maintain immune tolerance
- Functions similarly to PD-1/PD-L1 pathway
Cancer Treatment Potential
- High levels found in lung, liver, and colorectal cancers
- Promising target for tumors resistant to standard treatments
- Can be combined with other immune checkpoint inhibitors
- Clinical trials ongoing for FGL1-targeted therapies
Research Challenges
- Need to balance metabolic functions with cancer treatment
- Concerns about liver function impact during treatment
- Requires better biomarker identification
- Important to identify suitable patient populations
- Research continuing into treatment optimization
Visit the BioSupply Ltd website for more information on Fibrinogen-Like Protein 1 (FGL1): Immune Modulation, Cancer Therapy Potential, and Metabolic Regulation